Search Results for: HRAS

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel BRAP BRCA1 associated protein
  • RAF activation
  • Negative regulation of MAPK pathway
  • Signaling by moderate kinase activity BRAF mutants
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Signaling downstream of RAS mutants
Novel BUB1 BUB1 mitotic checkpoint serine/threonine kinase
  • Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
  • Separation of Sister Chromatids
  • Resolution of Sister Chromatid Cohesion
  • RHO GTPases Activate Formins
  • Mitotic Prometaphase
  • EML4 and NUDC in mitotic spindle formation
Novel C6orf62 chromosome 6 open reading frame 62
Novel CAV1 caveolin 1
  • Triglyceride catabolism
  • eNOS activation
  • NOSTRIN mediated eNOS trafficking
  • Thyroxine biosynthesis
  • Basigin interactions
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • VEGFR2 mediated vascular permeability
  • RHOA GTPase cycle
  • Extra-nuclear estrogen signaling
  • RHOB GTPase cycle
  • RHOC GTPase cycle
  • CDC42 GTPase cycle
  • RAC1 GTPase cycle
  • RAC2 GTPase cycle
  • RHOD GTPase cycle
  • RHOQ GTPase cycle
  • RHOH GTPase cycle
  • RHOG GTPase cycle
  • RHOJ GTPase cycle
  • RAC3 GTPase cycle
  • RHOF GTPase cycle
  • FOXO-mediated transcription of cell cycle genes
  • RND3 GTPase cycle
  • RND2 GTPase cycle
  • RND1 GTPase cycle
  • SARS-CoV-1 targets host intracellular signalling and regulatory pathways
  • SARS-CoV-2 targets host intracellular signalling and regulatory pathways
  • Congenital generalized lipodystrophy (CGL)
Novel CCL4 C-C motif chemokine ligand 4
  • Chemokine receptors bind chemokines
  • G alpha (i) signalling events
  • Interleukin-10 signaling
Novel CDC123 cell division cycle 123
Novel CDC25A cell division cycle 25A
  • Transcription of E2F targets under negative control by DREAM complex
  • Polo-like kinase mediated events
  • Activation of ATR in response to replication stress
  • Ub-specific processing proteases
  • Cyclin E associated events during G1/S transition
  • Cyclin A/B1/B2 associated events during G2/M transition
  • Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A
  • Cyclin A:Cdk2-associated events at S phase entry
  • Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
Novel CDC25C cell division cycle 25C
  • Polo-like kinase mediated events
  • Activation of ATR in response to replication stress
  • RHO GTPases activate PKNs
  • TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
  • TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain
  • Cyclin A/B1/B2 associated events during G2/M transition
  • Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
  • Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
Novel CDH1 cadherin 1
  • Degradation of the extracellular matrix
  • Degradation of the extracellular matrix
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
  • Integrin cell surface interactions
  • Apoptotic cleavage of cell adhesion proteins
  • Adherens junctions interactions
  • RHO GTPases activate IQGAPs
  • InlA-mediated entry of Listeria monocytogenes into host cells
  • Regulation of CDH1 Function
  • Regulation of CDH1 mRNA translation by microRNAs
  • Degradation of CDH1
  • Regulation of CDH1 posttranslational processing and trafficking to plasma membrane
  • Formation of definitive endoderm
  • Transcriptional and post-translational regulation of MITF-M expression and activity
  • Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition
  • Developmental Lineage of Mammary Gland Luminal Epithelial Cells
  • Developmental Lineage of Mammary Gland Myoepithelial Cells
  • Developmental Lineage of Mammary Stem Cells
  • Penile cancer
  • Breast cancer
  • Gastric cancer
  • Nasopharyngeal cancer
  • Hepatocellular carcinoma
  • Thyroid cancer
Novel CDKN2A cyclin dependent kinase inhibitor 2A
  • Oxidative Stress Induced Senescence
  • Senescence-Associated Secretory Phenotype (SASP)
  • Oncogene Induced Senescence
  • Cyclin D associated events in G1
  • Transcriptional Regulation by VENTX
  • Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4
  • Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
  • Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4
  • Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
  • Regulation of MITF-M-dependent genes involved in cell cycle and proliferation
  • Apoptotic factor-mediated response
  • Oxidative Stress Induced Senescence
  • Oncogene Induced Senescence
  • SUMOylation of DNA damage response and repair proteins
  • SUMOylation of transcription factors
  • Regulation of TP53 Degradation
  • Stabilization of p53
  • Regulation of RUNX3 expression and activity
  • Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function
  • Evasion of Oncogene Induced Senescence Due to p14ARF Defects
  • Evasion of Oxidative Stress Induced Senescence Due to p14ARF Defects
  • Nuclear events mediated by NFE2L2
  • Chronic myeloid leukemia (CML)
  • Non-small cell lung cancer
  • Malignant islet cell carcinoma
  • Adult T-cell leukemia
  • Esophageal cancer
  • Glioma
  • Pancreatic cancer
  • Nasopharyngeal cancer
  • Hepatocellular carcinoma
  • Squamous cell carcinoma
  • Penile cancer
  • Oral cancer
  • Malignant melanoma
  • Burkitt lymphoma
  • Gallbladder cancer
  • Bladder cancer
  • Laryngeal cancer
  • Cholangiocarcinoma
  • Malignant pleural mesothelioma
  • Osteosarcoma
  • Type II diabetes mellitus
Novel CTNNA1 catenin alpha 1
  • Adherens junctions interactions
  • VEGFR2 mediated vascular permeability
  • Myogenesis
  • Myogenesis
  • RHO GTPases activate IQGAPs
  • Regulation of CDH11 function
  • Regulation of CDH19 Expression and Function
  • Regulation of CDH1 Function
  • Degradation of CDH1
  • CDH11 homotypic and heterotypic interactions
Novel CXCL1 C-X-C motif chemokine ligand 1
  • Chemokine receptors bind chemokines
  • G alpha (i) signalling events
  • Interleukin-10 signaling
  • Neutrophil degranulation
Novel DEAF1 DEAF1 transcription factor
Novel DGKE diacylglycerol kinase epsilon
  • Effects of PIP2 hydrolysis
  • alpha-Tocopherol succinate
Novel DGKZ diacylglycerol kinase zeta
  • Effects of PIP2 hydrolysis
  • alpha-Tocopherol succinate
Novel DPP9 dipeptidyl peptidase 9
Novel EIF3L eukaryotic translation initiation factor 3 subunit L
  • L13a-mediated translational silencing of Ceruloplasmin expression
  • Translation initiation complex formation
  • Formation of a pool of free 40S subunits
  • Formation of the ternary complex, and subsequently, the 43S complex
  • Ribosomal scanning and start codon recognition
  • GTP hydrolysis and joining of the 60S ribosomal subunit
Novel ERBB2 erb-b2 receptor tyrosine kinase 2
  • Signaling by ERBB2
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • GRB7 events in ERBB2 signaling
  • Downregulation of ERBB2:ERBB3 signaling
  • GRB2 events in ERBB2 signaling
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Sema4D induced cell migration and growth-cone collapse
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Constitutive Signaling by Overexpressed ERBB2
  • Drug-mediated inhibition of ERBB2 signaling
  • Signaling by ERBB2 KD Mutants
  • Resistance of ERBB2 KD mutants to trastuzumab
  • Resistance of ERBB2 KD mutants to sapitinib
  • Resistance of ERBB2 KD mutants to tesevatinib
  • Resistance of ERBB2 KD mutants to neratinib
  • Resistance of ERBB2 KD mutants to osimertinib
  • Resistance of ERBB2 KD mutants to afatinib
  • Resistance of ERBB2 KD mutants to AEE788
  • Resistance of ERBB2 KD mutants to lapatinib
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Drug resistance in ERBB2 TMD/JMD mutants
  • Developmental Lineage of Mammary Gland Luminal Epithelial Cells
  • Developmental Lineage of Mammary Gland Myoepithelial Cells
  • Developmental Lineage of Mammary Stem Cells
  • Trastuzumab
  • Lapatinib
  • IGN311
  • Trastuzumab emtansine
  • Varlitinib
  • AV-412
  • Pertuzumab
  • Afatinib
  • Tucatinib
  • Tesevatinib
  • Fostamatinib
  • Brigatinib
  • Margetuximab
  • Zanubrutinib
  • Breast cancer
  • Cervical cancer
  • Cholangiocarcinoma
  • Pancreatic cancer
  • Gastric cancer
  • Ovarian cancer
  • Choriocarcinoma
  • Endometrial Cancer
  • Bladder cancer
Novel FBXW7 F-box and WD repeat domain containing 7
  • Association of TriC/CCT with target proteins during biosynthesis
  • Neddylation
  • Antigen processing: Ubiquitination & Proteasome degradation
Novel FNTA farnesyltransferase, CAAX box, subunit alpha
  • Apoptotic cleavage of cellular proteins
  • Inactivation, recovery and regulation of the phototransduction cascade
  • RAS processing
  • Potential therapeutics for SARS
  • AZD3409
  • Lonafarnib
  • 2-CHLORO-5-(3-CHLORO-PHENYL)-6-[(4-CYANO-PHENYL)-(3-METHYL-3H-IMIDAZOL-4-YL)- METHOXYMETHYL]-NICOTINONITRILE
  • (11S)-8-CHLORO-11-[1-(METHYLSULFONYL)PIPERIDIN-4-YL]-6-PIPERAZIN-1-YL-11H-BENZO[5,6]CYCLOHEPTA[1,2-B]PYRIDINE
  • L-778123
  • [(3,7,11-TRIMETHYL-DODECA-2,6,10-TRIENYLOXYCARBAMOYL)-METHYL]-PHOSPHONIC ACID
  • Farnesyl diphosphate
  • Geranylgeranyl diphosphate
  • ALPHA-HYDROXYFARNESYLPHOSPHONIC ACID
  • 2-[METHYL-(5-GERANYL-4-METHYL-PENT-3-ENYL)-AMINO]-ETHYL-DIPHOSPHATE
  • (20S)-19,20,21,22-TETRAHYDRO-19-OXO-5H-18,20-ETHANO-12,14-ETHENO-6,10-METHENO-18H-BENZ[D]IMIDAZO[4,3-K][1,6,9,12]OXATRIAZA-CYCLOOCTADECOSINE-9-CARBONITRILE
  • (20S)-19,20,22,23-TETRAHYDRO-19-OXO-5H,21H-18,20-ETHANO-12,14-ETHENO-6,10-METHENOBENZ[D]IMIDAZO[4,3-L][1,6,9,13]OXATRIAZACYCLONOADECOSINE-9-CARBONITRILE

Page 2 out of 16 pages